Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma 15-06-2012.

Slides:



Advertisements
Similar presentations
Contemporary practice of radiotherapy post radical prostatectomy at a tertiary referral centre in Australia Introduction  Adverse features on histopathology.
Advertisements

NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Rising PSA after Radical Prostatectomy. My Approach. Dr Manish Patel Urological Cancer Surgeon Urological Cancer Surgeon Westmead Hospital University of.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Rectal Cancer: A Complete Clinical Response…Now what?
Radiation Therapy in Prostate Cancer Current Status and New Advances Mahdi Aghili MD,AFSA Cancer Institute -Department of Radiation Oncology Associated.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Imaging modalities in prostate cancer
Stephen Ko, M.D. Mayo Clinic Jacksonville
3D Prostate Mapping Biopsies
CA of Prostate:Incidence In a 50 y/o man In a 50 y/o man In autopsy: 40% In autopsy: 40% Clinical: 10% Clinical: 10% Death: 3% Death: 3% Most common non-cutanous.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
Steven Joniau Filip Ameye
Prostate Radiotherapy A-Z
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”
IN RADIOTERAPIA BEST PAPERS 2014 FILIPPO ALONGI Direttore Unità Operativa Complessa Radioterapia Oncologica.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.
Prostate VTP: Clinical Trial Update
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.
Prostate Cancer Treatment: What’s Best For You?
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Laparoscopic Radical Prostatectomy: Oncological and Functional Outcomes Following Fellowship Training. Introduction Radical Prostatectomy (RP) is a technically.
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Rashid TG, Dudderidge T, Zahur S, Kini M, Ogden CW.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
PATTERNS OF CARE OF PATIENTS WITH AN OCCULT LOCOREGIONAL RELAPSE ON CHOLINE PET/CT AFTER A PRIOR CURATIVE TREATMENT FOR LOCALIZED PROSTATE CANCER Choline.
David Spellberg, MD Naples Urological Associates High Intensity Focused Ultrasound Sonablate ® HIFU A Minimally Invasive Way to Treat Prostate Cancer.
SC-PM6: Prediction Models in Medicine: Development, Evaluation and Implementation Michael W. Kattan, Ph.D. Ewout Steyerberg, Ph.D. Brian Wells, M.S., M.D.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.
David Spellberg, M.D., FACS Naples Urology Associates, P.A.
LOCAL TREATMENT OF OLIGOMETASTATIC DISEASE IN PROSTATE CANCER: LYMPHADENECTOMY Alberto Briganti, MD, fEBU Department of Urology Chair, Prostate Cancer.
Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by 11 C-Choline PET/CT RJ Karnes MD, FACS Vice-Chair Associate Professor and.
Salvage Radical Prostatectomy Salvage Radical Prostatectomy RJ Karnes MD, FACS RJ Karnes MD, FACSVice-Chair Associate Professor and Consultant Dept. of.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
HOW TO WRITE THE RESULTS SECTION
Surgical Treatment in Locally Advanced Prostate Cancer
Bladder Cancer and Prostatic Cancer
Prostate cancer นพ.ชัชชัย หอมเกตุ.
Nat. Rev. Urol. doi: /nrurol
Decipher Prostate, Decipher Bladder and Decipher GRID
New Tracers for Prostate Cancer Imaging
The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:
Post Op Positive Seminal Vesicle Case 4: Prostate_4
Prostate Cancer: Highlights from 2006
Volume 73, Issue 5, Pages (May 2018)
Apollo Gleneagles Hospitals,
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
What is New in Hormone Therapy for Prostate Cancer in 2007?
Volume 71, Issue 5, Pages (May 2017)
Nat. Rev. Urol. doi: /nrurol
EARLY AND LATE COMPLICATIONS OF PROSTATE LOW DOSE BRACHYTHERAPY
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Presentation transcript:

Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma

Treatment options Local recurrence after RP Radiotherapy ADT if N+ M+ Other options (off label)

Treatment options Local recurrence after Radiation treatments Salvage RP Salvage Cryo Brachy (small series) Re-radiation (off label)

Salvage RP Feasible? Safe? Effective?  Select cases!

PSA free (3-yr  75% PSA<0.2) Continence (7/32  22%) Sexual function(3/32  9%)

Treatment options Local recurrence after Radiation treatments Salvage RP Salvage Cryo Brachy (small series) Re-radiation (off label)

p: ns

Treatment options Local recurrence after Radiation treatments Salvage RP Salvage Cryo Salvage HIFU Brachy (small series) Re-radiation (off label)

Our experience Jan Jan salvage cryo (radiorecurrent PCa) Median age 73 (IQR 70-76) Minimum follow-up 15 months All patients underwent biopsy, and 18 F-choline PET-CT scan 4 cases underwent inguinal LNd  excluded (pN+)

Patients characteristics 7 cases not receiving ADT Median PSA 4.11ng/mL (IQR 1.3-5) Mean Gleason score 7.4 (range 6-9) 17 cases receiving ADT Median PSA 3.13 ng/mL (IQR ) Any of these successfully discontinued ADT!

PSA free survival 24-mo (Phoenix criteria)56% 21-monot ADT 65.6% 21-mounder ADT57.6% 24-mo (ASTRO criteria)53.6% 21-monot ADT 80% 21-mounder ADT60% Local recurrence Biopsy at physician discretion! 2 positive out of 6 performed 1 seminal vesicle recurrence at 18F-chol PET-CT Bifecta in patients not receiving ADT 72%

18 F-choline PET-CT No report on nodal or distant metastasis A step forward “biochemical recurrence” In our series 2 cases of nodal recurrences 4 cases with preoperative evidence of pos nodes confirmed by hystology

Preop CT and bone scan negative 3 mo PSA 1  6 mo PSA 2 PET-CT  Stereotaxic RT and ADT 32 mo PSA 0.8

Complications Urinary Incontinence  20% Rectal fistula  4% Previous simple prostatectomy and RT Sloughing and AUR requiring TURP  12.5%

Hot Topics Seminal Vesicles Discontinuing ADT? N+? M+? 2-yr ADT after adjuvant RT recommended Sloughed tissue and AUR requiring TURP  12.5%

Yes Low complication rate Minimally invasive treatment Learning curve salvage cryo vs salvage RP Patients selection!!! Previous TURP-simple prostatectomy Bifecta outcome >70%

Buts Cancer control lower than salvage RP Pts receiving ADT should not discontinue it Preoperative staging limits (rule out N+/M+) 18 F chol PET-CT has not 100% accuracy Bifecta-ASTRO-Phoenix can not be compared with undetectable PSA after RP Standardize outcome evaluation

Patient counseling Salvage RP is the radical treatment Healthy pts with life expectancy > 10yrs should be counseled accordingly… Local recurrence can be successfully treated with recryo or with ADT 10 yr Cancer specific survival  90%

Treatment options Local recurrence after Radiation treatments Salvage RP Salvage Cryo Salvage HIFU Brachy (small series) Re-radiation (off label)

Patient counseling Salvage RP is the radical treatment Healthy pts with life expectancy > 10yrs should be counseled accordingly… Local recurrence can be successfully treated with recryo or with ADT 10 yr Cancer specific survival  90%